The production of N-linked recombinant glycoproteins is possible in a variety of biotechnology host cells, and more recently in the bacterial workhorse, Escherichia coli. This methods chapter will outline the components and procedures needed to produce N-linked glycoproteins in E. coli, utilizing Campylobacter jejuni glycosylation machinery, although other related genes can be used with minimal tweaks to this methodology. To ensure a successful outcome, various methods will be highlighted that can confirm glycoprotein production to a high degree of confidence, including the gold standard of mass spectrometry analysis.
Introduction
The process of glycosylation, a posttranslational modification estimated to be present on half of all human proteins [1. 2] , can affect a wide variety of protein properties including its function, localization and half-life [3] [4] [5] . Due to these properties, 40 % of the drugs approved in the current recombinant therapeutics market are glycosylated, with this figure predicted to increase [6] . This sizeable market share means that glycoproteins contribute significantly to the biopharma industry, which in 2013 was calculated to be worth $US140 billion [7] .
Of the approved glycotherapeutics, approximately 70 % are currently being produced in the eukaryotic cell line, Chinese hamster ovary (CHO) cells [8] , which, through the utilization of their inherent glycosylation machinery, can mimic human type glycans, yielding therapeutic proteins with the desired glycosylation profile that will not induce an immunogenic response in humans [9] .
In the non-glycosylated therapeutic protein market, the main host cell factory is E. coli, which generates around 30 % of the 151 recombinant therapeutics approved by either the EMA or the FDA [10] . With recent advancements in the synthetic biology toolkit for E. coli, this host now has the ability to express full length monoclonal antibodies [11, 12] , and generate recombinant O-and Nlinked glycoproteins [13] [14] [15] [16] [17] . These new capabilities present the opportunity to generate recombinant glycoproteins within E. coli.
The initial discovery of bacterial N-linked glycosylation in C. jejuni and its successful transfer into E.
coli [16, 18] opened up this area of research. As the field has advanced and accumulated knowledge on the bacterial glycosylation system, variations on the initial system containing the defined pgl pathway allowed the first steps in creating a model cell chassis. This has provided the opportunity for researchers to experiment with different genetic components within the system, replacing them with alternative parts from a variety of organisms, including eukaryotes [14, 19] . This led to the creation of a wide range of different glycan structures that could be attached [14, 16, 19] , with a commercially successful example of this coming from the generation of glyco vaccines by GlycoVaxyn [20, 21] .
With an ever expanding number of glycan structures still being discovered in the archaeal and prokaryotic domains of life, the potential to transfer them to target proteins for currently unexplored uses is a promising prospect for the field [22, 23] .
Although the option to engineer this system is apparent, in order to be able to carry out bacterial Nlinked glycosylation, there are a few core components required. Firstly, the genes required for sugar biosynthesis within the cytoplasm must be functional [24] . Second of all, the glycosyltransferases which transfer these monosaccharides and sequentially build the glycan on the lipid anchor must be present [25] . An enzyme to flip the anchored glycan across to the periplasm needs to be expressed [26, 27] , and finally, an oligosaccharyl transferase (OSTase) that transfers the glycans to the target protein must also be functional within the system [28] . The structure and composition of the glycan, how efficiently it is flipped across the membrane and ultimately transferred to the target protein, are dependent on the genes introduced [14, 29, 30] . Here, we will outline the required components for producing glycoproteins in E. coli based upon the original C. jejuni system.
Oligosaccharyl Transferase and the Consensus Sequence that it can recognize within the

Target Protein
In eukaryotes, N-linked glycosylation occurs at the consensus site of N-X-S/T, where X can be any amino acid except proline. The recognition of this site and subsequent transfer of glycan onto the asparagine residue is dependent on a multi subunit (OSTase) complex with a core functional unit known as STT3 [31] . In bacteria, this OST is a large single protein, with the most commonly utilized transferase being a periplasm located, membrane bound protein called pglB [32] [33] [34] . The native form of this protein recognizes a stricter glycosylation sequon with the requirement of a negatively charged amino acid at the -2 position, giving the consensus sequence, D/E-X-N-X-S/T, again with X being any amino acid except proline. When thinking about utilizing this system for glycoprotein production, it is vital that this sequence is present, unless the machinery has been modified to include an OSTase that recognizes the eukaryotic glycosylation sequence [30] . Even so, this may not be sufficient for glycosylation to occur. Within eukaryotes, the process takes place in multiple steps as the protein is folded through two eukaryotic organelles, the ER and golgi [35, 36] , making it a cotranslational process [37] . Within these organelles, the glycan structure can be built up and subsequently trimmed down by processing enzymes before final glycans are added to produce the mature glycan structure [38] . In bacteria, glycosylation typically takes place in the periplasm of the cell [22] , and is seen as a single step block transfer of the final glycan to the target protein [39] , which occurs posttranslationally. Due to this occurring on a fully folded substrate, it requires the consensus sequence to be situated in a flexible region of the protein that is accessible to the OSTase [39] .
Periplasmic Localization
As mentioned in the previous section, attachment of the glycan onto the protein within bacteria occurs in the periplasm. Therefore, the target protein, glycan and OSTase need to be localized to this compartment of the cell. PglB, as highlighted previously, is a membrane bound protein located in the periplasm, so is already present. As for the target protein, there are multiple pathways available that will direct the target protein to this part of the cell, including the TAT export system [40] , SRP pathway [41] , and sec transport system [42] . The most utilized methodology is the sec transport system, which requires the addition of a 22 amino acid leader sequence at the N-terminus of the polypeptide chain. This can be engineered through molecular cloning of the expression plasmid, but it is recommended that protein expression and translocation rates be attenuated prior to glycoprotein production. Finally, the glycan of interest must be present in the periplasm. Within the bacterial system, the glycans are sequentially built upon an undecaprenyl-pyrophosphate (UND-pp) lipid anchor by various glycosyltransferases. Depending on the glycan structure, certain sugar biosynthesis genes must also be expressed that utilize molecules from the central carbon metabolism, modifying them to generate any unnatural glycan precursors such as bacillosamine, as well as the common monosaccharides like UDP-GlcNAc [43] . Once these have been generated, the glycosyltransferases transfer them to the glycan being built upon the lipid anchor. Once the glycans are attached, the UNDpp linked glycan molecule can be flipped across the inner membrane by a flippase, such as the C. jejuni pglK [34] , or the native E. coli protein wzX [44] so the glycan now faces the periplasm [19] .
With wzX and waaL, E. coli has a native system that utilizes periplasmic UND-pp linked glycans for attachment to a lipid A core, for subsequent presentation on the cell surface [15] . It is therefore recommended that for recombinant N-linked glycoprotein expression, the competing protein that transfers the glycans to the lipid A core, waaL, is removed as seen in the W3110 mutant, CLM24 [15] . The presence of waaL may be utilized to detect the presentation of glycans on the surface as a means of checking whether they are being expressed (or not) [32, 45] .
Conclusion of Requirements
The target recombinant protein must contain an asparagine residue situated in a consensus sequence, located in a flexible region of the protein, so that the OSTase of choice is able to recognize and bind.
Once expressed, it must also be directed to the periplasm for this type of glycosylation to occur, which can be achieved by utilizing a number of export systems. Alongside expression of the target protein, glycosylation machinery must be incorporated into the cell, containing any genes needed for specific sugar biosynthesis, the required glycosyltransferases to build the glycan, a flippase that can recognize the glycan as a substrate, and an OSTase that will also recognize the glycan. This should all preferably take place in a bacterial strain where the waaL pathway is inhibited, unless glycan production is being checked by cell surface display.
General Analysis
In order to determine if the target protein has been successfully glycosylated, it is necessary to perform a periplasmic extraction, to release proteins that have the potential to be glycosylated. In order to determine whether N-glycosylation of the target protein is successful, a number of methodologies can be applied with varying degrees of speed and accuracy. These include western blots, where a mass shift for the addition of a glycan is observed [32] , lectin peroxidase screen whereby a lectin that binds to a target glycan is bound [32] or the gold standard is the use of mass spectrometry, which can provide both protein sequence and glycan information [33] . By following the methodology and workflow stated (see Figure 1) , the user should be able to generate N-linked glycoproteins in E. coli and validate this production using a variety of techniques. For more details on bacterial glycosylation please refer to this extensive review paper [46] .
2 Materials
All solutions should be prepared using either nuclease-free water or HPLC grade water along with analytical grade reagents. All solutions should be made up at room temperature unless otherwise stated. All examples and methodologies listed are for the generation of IFN 2b with an N-linked glycan structure of GalNAc 5 GlcNAC within E. coli, utilizing the plasmids pJExpressIFN 2b and pACYCpgl2.
General and Experiment Specific Reagents, Strains and Plasmids
Antibiotic Stock Solutions
1. 50 mg/mL Kanamycin, filter sterilized.
2. 30 mg/mL Chloramphenicol in 100 % ethanol.
Bacterial Strains
1. E. coli W3110.
2. E. coli CLM24.
Glycosylation Machinery
1. pACYCpgl2.
Target Protein
1. pJexpressIFN 2b. 7. ImageQuant™ RT ECL (GE Healthcare) fitted with temperature cooled 16-bit CCD Camera.
Cell Surface Expression of Glycans
1-
Step TMB Ultra blotting solution (Thermo Fisher Scientific).
Target Protein Expression and Localization
1. Luria Broth: 10 g/L Tryptone, 10 g/L NaCl 5 g/L Yeast extract.
2. 1 mM IPTG. 2. Centrifuge capable of spinning 50 mL falcon tubes at 3,000 x g, 4°C.
Periplasmic Protein
Quantification
Bradford reagent (Sigma Aldrich).
2. RC DC protein assay kit II (Bio-Rad).
SDS-PAGE Gels and Analysis
SDS-PAGE
1. NuPAGE Novex 4-12 % Bis-Tris protein gels, 1.0 mm, 12 well (Life Technologies).
20 x Novex MOPS SDS running buffer (Life Technologies).
3. Novex Sharp Pre-stained protein standard (Life Technologies).
4. Hoefer SE300 miniVE integrated vertical electrophoresis unit (Hoefer Inc).
5. Centrifuge capable of spinning 1.5 mL microcentrifuge tubes at 13, 000 x g.
2. Inoculate 1 mL of LB, with the appropriate antibiotics, in a sterile 1.5 mL centrifuge tube with a colony of the bacterial strain containing pACYCpgl2.
3. Incubate the tube at 37 °C for 16 hours in a shaker at 180 rpm.
4. Measure the O.D. 600 and normalize the O.D. down to 0.6 using sterile LB.
5. Dilute the cells by a factor of 1 in 75,000 to a final volume of 1 mL.
6. Take 100 µL of the diluted culture and streak out onto an LB agar plate with correct antibiotics and leave to incubate for 16 hours at 37 °C (see Notes 1 and 2).
7. Soak a piece of nitrocellulose paper, cut to fit inside a petri dish, for 5 mins in the required antibiotics for the maintenance of the plasmid in the strain.
8. Place the nitrocellulose paper in a flow hood for 5 mins before placing the paper over the bacterial colonies using a clean pair of laboratory tweezers, and incubating for 3 hours at 37
°C (see Note 3). 12. Wash the membrane for 2 x 10 mins in PBS.
13. Detect colonies using Immobilon™ chemiluminescent HRP substrate with ImageQuant™ RT ECL (GE Healthcare), fitted with a cooled 16-bit CCD camera.
14. If this type of camera is not available, the screen can be developed using approximately 10 mL TMB-Ultra Blotting solution and leaving the membrane to develop for between 5-30 mins depending on the desired intensity and the level of background development.
15. Wash with 2 x 5 mins washes with HPLC grade water to stop development of the membrane (see Note 5).
Target Protein Expression and Localization
Bacterial Growth and Protein Expression
Required to check protein of interest is being expressed and translocated to the periplasm (see Figure   4 ).
1. Inoculate 10 mL of LB containing the appropriate antibiotics with a colony of CLM24 pJexpressIFN 2b and grow for 16 hours at 37 °C with shaking at 180 rpm.
2. Using the starter culture, inoculate 100 mL of LB containing the appropriate antibiotics and leave to grow at 37 °C with shaking at 180 rpm. 6. Discard supernatant and continue to periplasmic protein extraction (see Note 6).
Periplasmic Protein Extraction
1. Gently resuspend the bacterial pellet in 1 mL of ice cold periplasmic lysis buffer, keeping the suspension in a 50 mL Falcon tube.
2. Leave the pellet to gently roll on ice for 1.5 -2 hours.
3. Spin down the cell debris at 3,000 x g for 10 mins at 4 °C, collecting the supernatant as the periplasmic extract (see Note 7).
4. Pellet can be retained and the rest of the soluble fraction extracted to analyze the quantity of the target protein that has not been exported to the periplasm but has still been expressed.
Quantification of the Periplasmic Extract
Many common laboratory methods can be used here including a Bradford assay, RC/DC assay or nanodrop. Due to the frequent nature of these protocols, we advise that the researcher follows the detailed protocols that are widely available for these quantification techniques.
SDS-PAGE
1. Pre-cast protein gels were used to run the gel based analysis. 
Western Blotting
1. Western blotting will be conducted using the Invitrogen iBlot system and compatible transfer stacks. 12. Wash with 2 x 5 mins washes with HPLC grade water to stop development of the membrane.
Expression of Glycoprotein
See section 3.2.1 as the protocol for this is the same needed for glycoprotein expression except the starting bacterial strain must contain the plasmids required for both the target protein expression and the glycosylation machinery. Due to the presence of two plasmids, an extra antibiotic will be required for plasmid maintenance. If a mass spectrometry approach is going to be utilized for glycoprotein validation, it is important that when extracting the periplasmic proteins (section 3.2.2) no protease inhibitor cocktail is present in the lysis buffer mentioned earlier and that the sample is kept cold at all times (see Note 15).
Validation of Glycoprotein Production using Gel based methods
Western Blot Analysis
Expecting to see multiple bands compared to the control due to the mass shift that occurs with the attached glycan (see Figures 5 and 6 ). Run subsequent quantification steps (section 3.2.3), SDS-PAGE (section 3.2.4) and Western blot (section 3.2.5) analysis as outlined above as well as a lectin screen specific to the sugars incorporated in the glycan.
Lectin Screen
Sugar specific lectin should bind to the glycans if present.
1. Follow the same protocol as the western blotting up to step 5 with dismemberment of the blotting stack but instead of placing the membrane in the western blocking buffer, the membrane must be washed with PBS containing 2 % (v/v) Tween 20 for 2 mins at room temperature.
2. Post blocking, wash the membrane twice with PBS for 10 mins at room temperature. 
Validation of Glycoprotein Production using Mass Spectrometry Analysis
Expecting to see the presence of diagnostic ions correlating to the sugars involved in the glycan (see Figures 5 and 7) .
In-Solution Digest
1. In a single LoBind 1.5 mL centrifuge tube, add the required volume of the periplasmic extract to place 5 µg of protein into the tube.
2. Make up the total volume to 40 µL using 100 mM ammonium bicarbonate. 
